Human CD20 Antibody - Rituximab Biosimilar

Human IgG1 monoclonal antibody (mAb) against human CD20

Anti-hCD20-hIgG1 is the biosimilar of the clinical antibody rituximab. Anti-hCD20-hIgG1 features the constant region of a human IgG1 isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the human CD20 antigen found on the surface of malignant and normal B lymphocytes.

The binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation, and cell-mediated cytotoxicity.

Rituximab has been approved by the FDA to treat various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.

Anti-hCD20-hIgG1 was generated by recombinant DNA technology. It has been produced in Chinese hamster ovary (CHO) cells and purified by affinity chromatography with protein G.

More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below or in the 'upon request' section). InvivoGen also provides type I and type II anti-hCD20 mAbs featuring the variable regions of Ofatumumab or Obinutuzumab, with either native or engineered Fc regions.